Navigation Links
CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
Date:2/17/2012

WASHINGTON, Feb. 17, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) today released the following statement regarding a new economic impact study that analyzed the potential economic consequences a prescription requirement for safe and effective cold and allergy medicines containing pseudoephedrine (PSE) would have on the state of Oklahoma. The study was conducted by the Economic Impact Group, LLC, and funded by a grant provided by the CHPA.

Some of the study's most compelling findings include the following impacts of a prescription requirement:  

  • An influx of more than 296,000 new doctor visits in Oklahoma, with costs reaching as much as $59 million in the state.
  • The productivity cost from missed days from work or school already accounts for an estimated $227 to $400 million from viral respiratory tract infections in Oklahoma.  These costs would climb considerably under a prescription requirement.

"The economic impact study in Oklahoma quantified what we already knew to be true: a prescription requirement for popular and reliable over-the-counter cold and allergy medicines will lead to higher healthcare costs for responsible consumers, lower productivity for Oklahoma businesses, and lost tax revenues for the state," said Scott Melville, president and CEO, CHPA. "Effectively reducing meth production in Oklahoma is a critically important goal, but it's important that methods employed to achieve that goal do not burden law-abiding Oklahomans with significant and unnecessary costs."

www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
2. Roche responds to announcement of IDEAL hepatitis C trial results
3. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
6. EPSScentral Responds to Pandemic Alert
7. Endologix Responds to Alleged Patent Infringement
8. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
9. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
10. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
11. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is ... 2016 to 2023 and reach a figure of $6.34 ... a chronic disease and is affecting a huge population. ... This report is focused on emerging cancer diagnostics market ... propelled due to factors such as: increasing number of ...
(Date:3/28/2017)... 28, 2017  Medeon Biodesign, Inc., a ... pleased to announce that the Company led and ... Orthopedics, Inc., a San Jose, CA ... for orthopedic extremity applications.  The ... primarily due to procedure volume growth, lifestyle influences ...
(Date:3/28/2017)... 28, 2017  "US Cancer Generics Market Outlook ... indicators and trend analysis related to the emergence ... pharmaceutical market in US. The report analyzes various ... on cancer generics drugs in recent years. The ... billions of dollars for various stake holders involved ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage some ... Time Square, New York. , The program will be led by co- ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual American ... Diabetes Risk Test to find out if they are at risk for developing Type ... up the evening sky by programming the LAX pylons the color red. Downtown’s U.S. ...
(Date:3/28/2017)... DC (PRWEB) , ... March 28, 2017 , ... ... on elected representatives in state legislatures and Congress to protect parental rights and ... public health and safety in America. , The demonstration coincides with a press ...
Breaking Medicine News(10 mins):